Afanix 40 mg (Generic Afatinib) – Beacon Pharmaceuticals

Afanix 40 mg is a generic formulation of Afatinib — a second-generation, irreversible EGFR/HER2 tyrosine kinase inhibitor — manufactured by Beacon Pharmaceuticals Ltd., Bangladesh’s largest dedicated oncology pharmaceutical company. Each tablet contains 40 mg of afatinib, the same active molecule found in Gilotrif® (Boehringer Ingelheim), and is dispensed under the Named Patient Program for patients requiring a quality-assured, affordable alternative.

Unlike first-generation EGFR inhibitors that bind reversibly, afatinib forms a permanent, irreversible bond with EGFR and HER2 — giving it activity against a broader range of EGFR mutations, including several uncommon mutations not well covered by other EGFR inhibitors.

In EGFR-mutated NSCLC, mutations such as exon 19 deletions or L858R cause the EGFR receptor to become permanently switched on, driving uncontrolled tumour growth. Afatinib irreversibly binds to and blocks not only EGFR but also HER2 and HER4 — a broader inhibition profile than first-generation EGFR inhibitors like erlotinib or gefitinib.

Afatinib has a notably different tolerability profile from osimertinib — skin and gastrointestinal side effects are more prominent and typically emerge early. Being prepared for this from day one improves the experience significantly.

• Week 1: Diarrhoea is the most common early side effect and can be significant. Your oncologist will likely recommend antidiarrhoeal medication at the first loose stool. Staying well hydrated is important from day one.
• Weeks 2–3: An acne-like rash commonly develops, most often on the face, scalp, and upper body. Mouth sores (stomatitis) and dry, sensitive skin may also emerge. Gentle skin care and sun protection help significantly.
• Week 4: Side effects often begin to settle as your body adjusts and management strategies take effect. Continue any prescribed antidiarrhoeal or skin care regimen consistently.

Afatinib’s side-effect profile is more pronounced than third-generation EGFR inhibitors, particularly affecting the skin and gastrointestinal tract. Most effects are manageable with proactive supportive care.

Standard dose: 1 tablet (40 mg) once daily, on an empty stomach — at least 1 hour before or 2 hours after eating.

• 1
  Once daily on an empty stomach — food significantly reduces afatinib absorption, so timing relative to meals matters more than with most other EGFR inhibitors.
• 2
  Swallow tablet whole with a full glass of water. Do not crush or chew.
• 3
  At the first sign of loose stool, start antidiarrhoeal treatment as instructed by your oncologist — do not wait for diarrhoea to worsen before acting.
• 4
  Sun protection is important — afatinib can cause skin sensitivity; use sunscreen and protective clothing outdoors.
• 5
  Storage: below 25°C, protected from moisture and light, out of reach of children.

• ♥
  Be ready for diarrhoea from day one — have antidiarrhoeal medication on hand as directed and encourage fluid replacement. This is the most common reason patients need dose adjustment on afatinib.
• ♥
  Support skin and mouth care — gentle, fragrance-free skin products and regular mouth rinses can reduce the severity of rash and mouth sores. Report worsening skin reactions promptly.
• ♥
  Help with meal timing — since Afanix must be taken on an empty stomach, help plan dosing around meals consistently to avoid missed or mistimed doses.